Meet Excelra at Bio-IT world 2026 – Booth #717

Track: AI for oncology, Precision medicine & Health

Identifying predictive biomarkers for patient stratification remains a critical challenge in rare and heterogeneous malignancies. Artificial intelligence (AI) and machine learning (ML)-driven approaches that integrate multi-modal molecular and clinical data can effectively predict treatment response and enable data-driven patient stratification. These approaches employ imputation, feature selection, regularization, and cross-validation to identify distinct molecular signatures associated with treatment response, stratify patients into likely responders and non-responders, and generate biologically relevant hypotheses on mechanisms of action and resistance. These findings highlight the transformative potential of AI in oncology, supporting the feasibility of ML-driven biomarker discovery and providing a scalable framework to advance clinical trial design, patient stratification, and precision medicine in data-constrained environments.

Date: May 20, 2026 at 4PM